Sandra Beaver Sells 2,423 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 2,423 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $12.72, for a total transaction of $30,820.56. Following the transaction, the chief financial officer now owns 151,778 shares in the company, valued at $1,930,616.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sandra Beaver also recently made the following trade(s):

• On Tuesday, March 19th, Sandra Beaver sold 5,672 shares of Evolus stock. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24.
• On Thursday, February 22nd, Sandra Beaver sold 1,821 shares of Evolus stock. The stock was sold at an average price of $13.08, for a total value of $23,818.68.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $13.28 on Thursday. The firm has a market cap of $831.46 million, a price-to-earnings ratio of -12.61 and a beta of 1.47. The stock has a fifty day simple moving average of $13.07 and a two-hundred day simple moving average of $11.71. The company has a current ratio of 3.21, a quick ratio of 2.96 and a debt-to-equity ratio of 6.54. Evolus, Inc. has a 1-year low of $7.07 and a 1-year high of $15.43.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. Analysts anticipate that Evolus, Inc. will post -0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EOLS has been the topic of a number of recent analyst reports. Barclays upgraded Evolus from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $16.00 in a report on Monday, January 29th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday, May 8th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Wednesday, May 8th.

Hedge Funds Weigh In On Evolus

Several large investors have recently modified their holdings of EOLS. Walleye Capital LLC lifted its stake in shares of Evolus by 650.1% during the 3rd quarter. Walleye Capital LLC now owns 293,084 shares of the company’s stock valued at $2,679,000 after buying an additional 254,013 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of Evolus by 3.0% during the fourth quarter. Stonepine Capital Management LLC now owns 5,333,004 shares of the company’s stock worth $56,157,000 after acquiring an additional 154,000 shares in the last quarter. Brandywine Global Investment Management LLC boosted its holdings in shares of Evolus by 1.9% in the third quarter. Brandywine Global Investment Management LLC now owns 158,200 shares of the company’s stock worth $1,446,000 after acquiring an additional 3,000 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Evolus in the third quarter valued at $1,200,000. Finally, Graham Capital Management L.P. raised its stake in shares of Evolus by 43.1% during the 3rd quarter. Graham Capital Management L.P. now owns 37,946 shares of the company’s stock valued at $347,000 after purchasing an additional 11,438 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.